PD-L1 Expression Is an Independent Marker for Lymph Node Metastasis in Middle Eastern Endometrial Cancer.
PD-L1
endometrial cancer
immunohistochemistry
lymph node metastasis
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
25 Feb 2021
25 Feb 2021
Historique:
received:
17
01
2021
revised:
20
02
2021
accepted:
23
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
7
3
2021
Statut:
epublish
Résumé
Programmed death ligand 1 (PD-L1) expression in endometrial cancer (EC) tumor cells have been reported in several studies with inconsistent results. Furthermore, there is scarcity of data on the prevalence and prognostic significance of PD-L1 expression in EC from Middle Eastern ethnicity. We aimed to assess PD-L1 expression in a large cohort of Middle Eastern EC and to correlate this with clinico-pathological factors, as well as mismatch repair (MMR) protein status and patients' outcome. PD-L1 expression was investigated using immunohistochemistry on tissue microarray in an unselected cohort of 440 EC. Kaplan-Meier and logistic regression analysis were used to compare the outcome and prognostic factors. PD-L1 expression in tumor tissue was detected in 18.9% (83/440) EC cases with no impact on survival. When stratified for MMR protein status, PD-L1 expression was similar for both MMR deficient and MMR proficient ECs. However, the expression of PD-L1 in tumor cells was significantly associated with type II (non-endometrioid) histology (
Identifiants
pubmed: 33669153
pii: diagnostics11030394
doi: 10.3390/diagnostics11030394
pmc: PMC7996603
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
Front Oncol. 2020 Apr 30;10:632
pubmed: 32426281
Am J Surg Pathol. 2017 Mar;41(3):326-333
pubmed: 27984238
Int J Mol Sci. 2018 Aug 13;19(8):
pubmed: 30104481
Am J Surg Pathol. 2016 Aug;40(8):1133-42
pubmed: 27158757
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Asia Pac J Clin Oncol. 2020 Apr;16(2):e108-e112
pubmed: 30411509
Int J Gynecol Pathol. 2018 Nov;37(6):564-574
pubmed: 30059455
Int J Gynecol Cancer. 2016 Jan;26(1):2-30
pubmed: 26645990
Gynecol Oncol. 2017 Jun;145(3):446-452
pubmed: 28347512
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Expert Rev Anticancer Ther. 2016;16(1):13-20
pubmed: 26588948
Saudi Med J. 2018 Dec;39(12):1259-1262
pubmed: 30520511
Gynecol Oncol. 2020 Apr;157(1):260-267
pubmed: 31973911
Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1708-18
pubmed: 16985034
Int J Gynecol Pathol. 2019 Sep;38(5):404-413
pubmed: 30134343
Cancer. 2015 Jun 1;121(11):1762-71
pubmed: 25712738
J Pathol. 2007 Oct;213(2):190-9
pubmed: 17703498
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Am Acad Dermatol. 2017 Sep;77(3):527-533
pubmed: 28716437
Cancer Cell Int. 2019 Dec 11;19:334
pubmed: 31866764
Ann Oncol. 2017 Mar 1;28(3):651-657
pubmed: 27864219
JAMA Oncol. 2015 Dec;1(9):1319-23
pubmed: 26181000
Ann Oncol. 2016 Mar;27(3):409-16
pubmed: 26681673
Oncol Lett. 2016 Aug;12(2):944-950
pubmed: 27446374
Oncologist. 2018 May;23(5):518-523
pubmed: 29386312
J Thorac Oncol. 2018 Aug;13(8):1156-1170
pubmed: 29777823
J Cutan Pathol. 2016 Aug;43(8):663-70
pubmed: 27153517
Mod Pathol. 2019 Apr;32(4):576-584
pubmed: 30401949
Gynecol Oncol. 2018 May;149(2):381-387
pubmed: 29572029
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Am J Surg Pathol. 2020 Feb;44(2):174-181
pubmed: 31651527
JAMA Oncol. 2019 Jan 1;5(1):74-82
pubmed: 30242306
Int J Gynecol Cancer. 2018 Jan;28(1):59-68
pubmed: 29053481
J Clin Oncol. 2016 Mar 10;34(8):833-42
pubmed: 26755520
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Clin Oncol. 2019 Nov 10;37(32):2987-2999
pubmed: 31403867
Gynecol Oncol. 2019 Aug;154(2):314-322
pubmed: 31204078
Lancet Oncol. 2019 Jun;20(6):849-861
pubmed: 31003911